Nicolas Dzamko1,2, Amanda M Gysbers2, Rina Bandopadhyay3, Marc F Bolliger4, Akiko Uchino5, Ye Zhao1, Masaki Takao5,6, Sandrine Wauters3, Wilma D J van de Berg7, Junko Takahashi-Fujigasaki5, R Jeremy Nichols4, Janice L Holton3, Shigeo Murayama5, Glenda M Halliday1,2. 1. School of Medical Sciences, University of New South Wales, Kensington, Australia. 2. Neuroscience Research Australia, Randwick, Australia. 3. Queen Square Brain Bank, UCL Institute of Neurology, University College London, London, UK. 4. Parkinson's Institute and Clinical Center, Sunnyvale, California, USA. 5. Department of Neuropathology, Brain Bank for Aging Research, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan. 6. Department of Neurology, Saitama Medical University, International Medical Centre, Saitama, Japan. 7. Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinson's disease; however, little is known about the expression of LRRK2 in human brain and if/how LRRK2 protein levels are altered in Parkinson's disease. OBJECTIVES: We measured the protein levels of LRRK2 as well as its phosphorylation on serines 910, 935, and 973 in the postmortem brain tissue of Parkinson's disease patients and aged controls with and without Lewy bodies. METHODS: LRRK2 and its phosphorylation were measured by immunoblot in brain regions differentially affected in Parkinson's disease (n = 30) as well as subjects with Lewy bodies restricted to the periphery and lower brain stem (n = 25) and matched controls without pathology (n = 25). RESULTS: LRRK2 levels were increased in cases with restricted Lewy bodies, with a 30% increase measured in the substantia nigra. In clinical Parkinson's disease, levels of LRRK2 negatively correlated to disease duration and were comparable with controls. LRRK2 phosphorylation, however, particularly at serine 935, was reduced with clinical Parkinson's disease with a 36% reduction measured in the substantia nigra. CONCLUSIONS: Our data show that LRRK2 phosphorylation is reduced with clinical PD, whereas LRRK2 expression is increased in early potential prodromal stages. These results contribute to a better understanding of the role of LRRK2 in idiopathic Parkinson's disease and may aid efforts aimed at therapeutically targeting the LRRK2 protein.
BACKGROUND:Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinson's disease; however, little is known about the expression of LRRK2 in human brain and if/how LRRK2 protein levels are altered in Parkinson's disease. OBJECTIVES: We measured the protein levels of LRRK2 as well as its phosphorylation on serines 910, 935, and 973 in the postmortem brain tissue of Parkinson's diseasepatients and aged controls with and without Lewy bodies. METHODS:LRRK2 and its phosphorylation were measured by immunoblot in brain regions differentially affected in Parkinson's disease (n = 30) as well as subjects with Lewy bodies restricted to the periphery and lower brain stem (n = 25) and matched controls without pathology (n = 25). RESULTS:LRRK2 levels were increased in cases with restricted Lewy bodies, with a 30% increase measured in the substantia nigra. In clinical Parkinson's disease, levels of LRRK2 negatively correlated to disease duration and were comparable with controls. LRRK2 phosphorylation, however, particularly at serine 935, was reduced with clinical Parkinson's disease with a 36% reduction measured in the substantia nigra. CONCLUSIONS: Our data show that LRRK2 phosphorylation is reduced with clinical PD, whereas LRRK2 expression is increased in early potential prodromal stages. These results contribute to a better understanding of the role of LRRK2 in idiopathic Parkinson's disease and may aid efforts aimed at therapeutically targeting the LRRK2 protein.
Authors: Joseph M Thomas; Xiaobo Wang; Gongbo Guo; Tianxia Li; Bingling Dai; Leslie G Nucifora; Frederick C Nucifora; Zhaohui Liu; Fengtian Xue; Chunfeng Liu; Christopher A Ross; Wanli W Smith Journal: J Cell Physiol Date: 2020-03-17 Impact factor: 6.384
Authors: Shijie Wang; Zhiyong Liu; Tao Ye; Omar S Mabrouk; Tyler Maltbie; Jan Aasly; Andrew B West Journal: Acta Neuropathol Commun Date: 2017-11-22 Impact factor: 7.801
Authors: Ye Zhao; Gayathri Perera; Junko Takahashi-Fujigasaki; Deborah C Mash; Jean Paul G Vonsattel; Akiko Uchino; Kazuko Hasegawa; R Jeremy Nichols; Janice L Holton; Shigeo Murayama; Nicolas Dzamko; Glenda M Halliday Journal: Brain Date: 2018-02-01 Impact factor: 13.501
Authors: Shalini Padmanabhan; Thomas A Lanz; Donal Gorman; Michele Wolfe; Alison Joyce; Carlos Cabrera; Rosemary Lawrence-Henderson; Najah Levers; Neal Joshi; Thong C Ma; Christopher Liong; Sushma Narayan; Roy N Alcalay; Samantha J Hutten; Marco A S Baptista; Kalpana Merchant Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568